MSLN and familial pancreatic carcinoma: Thus, this immune competent mouse model replicates the poor in vivo therapeutic efficacy reported in early phase clinical trials of standard anti-mesothelin CAR T cells in pancreatic cancer (3), making it an ideal model in which to test enhancement of the CAR T cells with synthetic IL-2 circuits.